French ophthalmic company Nicox (Euronext Paris: COX) has advanced its strategy of building an international business by acquiring 100% of Doliage, and agreed with Austria's Marinomed Biotechnologies to acquire the Carragelose antiviral eyedrop program.
Pending shareholder approval, Nicox also plans to proceed with the acquisition of Aciex Therapeutics of the USA, as previously announced (The Pharma Letter July 2).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze